Product details

Regulatory note: Khavinson bioregulator (Russian scientific lineage); CAS commonly not registered. Confirm AEDL sequence and identity per batch COA, disambiguation from sibling tetrapeptides (AEDG / AEDP / KED) in the family is essential since the masses are close.

FAQ

How do I tell Bronchogen apart from its sibling Khavinson tetrapeptides (Epitalon, Cortagen)?

The Khavinson tetrapeptide family shares an Ala-Glu-Asp tripeptide core (AED-) and differs only in the fourth C-terminal residue: Bronchogen is AEDL (with Leucine), Epitalon is AEDG (Glycine), Cortagen is AEDP (Proline). The molecular weights are close (Bronchogen ≈432 Da, Epitalon ≈390 Da, Cortagen ≈400 Da, all within a 50 Da range), which means mass spec alone is insufficient to disambiguate, the molecules can be confused on the COA if only mass is reported. LC-MS/MS sequence verification covering the full b- and y-ion ladder is the definitive identity check. Buyers ordering any single Khavinson tetrapeptide should request explicit sequence-verification data on the batch COA, especially when sourcing from a new supplier.

What's the published Khavinson-school research context for Bronchogen specifically?

Khavinson-school publications on Bronchogen focus on respiratory-epithelium gene-expression effects in animal models of chronic bronchopulmonary disease and aging-related respiratory decline. The reported readouts include modulation of bronchial epithelial cell proliferation markers, antioxidant-enzyme expression in respiratory tissue, and improvements in pulmonary function metrics in aged-rat models. As with the rest of the Khavinson framework, the evidence base is concentrated in Russian-language journals and translated proceedings from the St. Petersburg Institute of Bioregulation and Gerontology, Western peer-reviewed coverage is limited and the mechanism-of-action data has not been independently replicated outside the Khavinson research lineage at the rigor level Western evidence-based-medicine frameworks expect. Buyers working with Bronchogen should reference the Khavinson primary literature for protocol design and treat the molecule as an investigational research tool.

What's the typical administration route used in Bronchogen research protocols?

Published Khavinson-school Bronchogen protocols use both intranasal and intramuscular administration routes. The intranasal route is the more commonly used in respiratory-focused research because direct delivery to the airway epithelium maximizes tissue exposure at the target organ. The intramuscular route produces systemic exposure that is appropriate for studies examining whole-organism effects rather than direct airway-tissue interaction. Working dilutions for intranasal preparation should use isotonic saline as the vehicle with neutral pH (5.5-7.0); benzalkonium chloride and similar quaternary-ammonium preservatives should be avoided in intranasal peptide formulations because they interact with short peptide sequences.

Certificate of Analysis (COA)